Queen Elizabeth II Health Sciences Centre

Accepting patients

DREAMM5

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more
  • Antibody Drug Conjugate (ADC)
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 2
  • Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials